George Yancopoulos, Regeneron’s longtime chief scientist, shared insights on how the biotechnology industry is evolving amid rapid advances in artificial intelligence and growing scrutiny over drug pricing. As one of the most influential figures in modern biotech, he reflected on how scientific leadership must balance innovation with responsibility in an increasingly complex healthcare landscape.
He emphasized that while artificial intelligence holds significant promise in accelerating drug discovery and improving research efficiency, it should be treated as a supporting tool rather than a replacement for deep biological understanding. According to him, real breakthroughs still depend on rigorous science, high-quality data, and experienced researchers who can interpret results thoughtfully.
Yancopoulos also addressed ongoing debates around drug pricing, defending the need for sustained investment in research and development. He argued that policies targeting prices must carefully consider the long timelines, high risks, and massive costs involved in bringing new therapies from the lab to patients, or they risk slowing medical progress.
Overall, his remarks highlighted a cautious but optimistic view of the future. He stressed that biotechnology, powered by both human expertise and advanced technologies like AI, can deliver transformative treatments — but only if companies remain committed to scientific integrity, patient benefit, and long-term innovation rather than short-term gains.
